Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH). More
Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH).
Bosentan monohydrate- is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH).
Bosentan; Tracleer; Ro 47-0203; Ro-47-0203
Bosentas
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide
It belongs to a class of drugs known as ERAs (endothelin receptor antagonists). Bosentan blocks the binding of endothelin to its receptors, by negating the endothelin's deleterious effects.
Start with 62.5 mg, twice daily for four weeks. For maintenance therapy, the drug dosage can be increased to 125 mg, twice daily.
For the treatment of pulmonary arterial hypertension.
Drugs such as warfarin, statins, diltiazem, Amiodarone, erythromycin, rifampicin, itraconazole, ketoconazole, fluconazole and tacrolimus may interact with Bosentan monohydrate.
Store at 20-25°C
551.614
C27H29N5O6S
147536-97-8
